 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The MEK inhibitor Selumetinib in the treatment of malignant tumors with MAPK pathway mutations

J Clin Oncol: The MEK inhibitor Selumetinib in the treatment of malignant tumors with MAPK pathway mutations

 Last Update: 2022-05-21
 Source: Internet
 Author: User

Tags

adrenal pathway

describe protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The NCI-COG Children's MATCH trial assigned patients aged 1-21 years with relapsed or refractory solid tumors, lymphomas , and histiocytic diseases into a phase II study for molecularly targeted therapy based on the detection of pre-defined genetic variants

Molecular targeting of childhood lymphoma

This article reports the outcomes of patients treated with selumetinib in this trial

Patients received selumetinib twice daily for 28 days until disease progression or unacceptable toxicity

The best remission status for 3 patients was stable disease

In conclusion, a national histology-unknown molecular screening strategy is effective in screening children and young adults for selumetinib therapy in the upcoming first pediatric MATCH treatment cohort

Screening for MEK inhibitors has shown promising efficacy in some pediatric tumors.

Original source:

Olive S.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dacarbazine CAS 4342-03-4 for Scientific Research Chemical Reagents Use only

CAS No.: 4342-03-4

Pharmacy Grade

$4-5/G FOB

Lapatinib 99% white powder CAS231277-92-2 bulk Lapatinib

CAS No.: 231277-92-2

Pharmacy Grade

$88-98/KG FOB

Mitomycin C

CAS No.: 50-07-7

Industrial Grade

$0.1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.